OFIRMEV® (Acetaminophen) Injection Health Economic Data Presented at 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
The analysis, titled "Estimating the Effect of Intravenous Acetaminophen (IV-APAP) on Length of Stay and Inpatient Costs," evaluated data from The
Key findings associated with incorporating OFIRMEV and reducing the use of opioids across these surgical patients were:
- An average 18% reduction in length of stay for the modeled scenario with an estimated annual cost savings of
$4.5 million ; - An average reduction in modeled complication rates of 28.5% with an estimated annual cost-savings of
$200,000 ; and - In aggregate, an estimated annual
$4.7 million in lowered costs, per a medium-sized hospital.
ABOUT THE DATA
Estimating the effect of intravenous acetaminophen (IV-APAP) on length of stay and inpatient costs.
Find the poster online: http://epostersonline.com/asra_RA16/node/723
IMPLICATIONS OF THE DATA
This analysis may provide important insight for surgeons, pharmacists and hospital administrators looking for possible ways to help improve patient outcomes and provide savings to the hospital system. The use of opioids alone has been a mainstay for acute pain management. There is an overreliance on opioids as monotherapy to treat acute pain in U.S. hospitals today and 7 out of 10 hospital patients treated with intravenous (IV) analgesia receive IV opioids alone.3
LIMITATIONS OF STUDY
Limitations associated with retrospective observational research designs include the following: ability to make causal inferences, reproducibility and generalizability.
ABOUT OFIRMEV (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection is indicated for the management of mild to moderate pain, management of moderate to severe pain with adjunctive opioid analgesics, and reduction of fever. OFIRMEV (acetaminophen) injection is the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States.
IMPORTANT RISK INFORMATION
WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Take care when prescribing, preparing, and administering OFIRMEV Injection to avoid dosing errors which could result in accidental overdose and death. In particular, be careful to ensure that:
- the dose in milligrams (mg) and milliliters (mL) is not confused;
- the dosing is based on weight for patients under 50 kg;
- infusion pumps are properly programmed; and
- the total daily dose of acetaminophen from all sources does not exceed maximum daily limits.
OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.
CONTRAINDICATIONS
- Acetaminophen is contraindicated in patients with:
-known hypersensitivity to acetaminophen or to any of the excipients in the intravenous (IV) formulation.
-severe hepatic impairment or severe active liver disease
ADVERSE REACTIONS
- Serious adverse reactions may include hepatic injury, serious skin reactions, hypersensitivity, and anaphylaxis.
- Common adverse reactions in adults include nausea, vomiting, headache, and insomnia. Common adverse reactions in pediatric patients include nausea, vomiting, constipation, pruritus, agitation, and atelectasis.
For additional Important Risk Information, including complete boxed warning, see Full Prescribing Information.
ABOUT
CONTACTS
Media
Senior Communications Manager
314-654-8618
rhonda.sciarra@mallinckrodt.com
Senior Vice President, Communications and Public Affairs
314-654-3318
meredith.fischer@mallinckrodt.com
Investor Relations
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
1 The average number of days a patient stays at the facility
2
3
Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ofirmev-acetaminophen-injection-health-economic-data-presented-at-41st-annual-regional-anesthesiology-and-acute-pain-medicine-meeting-300244230.html
SOURCE